Concerto Biosciences measures, maps, and harnesses the microbial world to create best-in-class therapies and products. These assets achieve real-world efficacy and durability through naturally occurring symbioses among microbes. Powering asset discovery is our intelligence platform: Our microbial community screening apparatus (kChip) generates the right data at the right scale (40M+ combinations constructed and measured so far) needed to train a generalized AI model (kAI) of microbial ecology. Our first market is skin health, where we’ve brought a live biotherapeutic candidate for eczema to the clinic (ENS-002, or “Ensemble No.2”, a trio of bacteria that counteracts S. aureus virulence) and formulated a postbiotic ferment for consumer use (CB-002). In our mission to solve diverse market pain points with microbial solutions, we are building a pipeline across dermatology, women’s health, and food science. Concerto partners with global organizations to bring our solutions to market, tapping into microbial ecology to meet 21st-century needs of people and planet.
Company Details
- Employees
- 33
- Founded
- -
- Address
- Cambridge, Ma, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.concertobio.com
- HQ
- Cambridge, MA
Concerto Biosciences Questions
Concerto Biosciences's website is http://www.concertobio.com
Concerto Biosciences's LinkedIn profile is https://www.linkedin.com/company/concerto-biosciences
Concerto Biosciences has
33 employees.
View email and phone details for 33
employees at Concerto Biosciences.
Concerto Biosciences's industry is
Biotechnology Research
Concerto Biosciences's top competitors are
Manifold Bio,
Glyphic Biotechnologies,
Pivot Bio,
Latchbio,
Switch Bioworks,
Parallel Bio,
64x Bio,
Gro Biosciences,
Asimov,
Nextrna Therapeutics.
Concerto Biosciences's categories are Biotechnology Research
Concerto Biosciences's founding year is 2020
